Biotech beat
The Clinical Trials beat on Biotech tracks 104 verified stories, with 3 clearing multi-source corroboration in the last 7 days at mean impact 5.7/10 — live SQLite counts, not editorial weighting.
4 stories
Beat pulse
Impact 5.7/10 (-0.3 vs prior). Counts are stories in our record, not a market forecast.
Open the change reportCoverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 33 percentage points.
Stories appear on this page because our classification stage assigned them this category as their primary topic — each story receives exactly one category per niche, chosen from a fixed list, so a story that touches both a funding round and a product launch in the same week sorts into whichever category best matches its dominant subject, not both. This keeps each category page focused on one beat rather than a blend of unrelated developments, and applies the same source-verification standard used across every story on this site. Sentiment measures the directional read of each development for this category specifically, not the tone of the reporting, and impact weights how consequential a development is — regulatory, financial, or operational — rather than how widely it was syndicated across outlets.
Figures are computed live from our source-verified story record (as of ) The volume change compares this window with the prior 7 days in the same record. — see our methodology for how impact and sentiment are derived.
Beat actors
Entities appearing in at least two verified clinical trials stories on this desk — ranked by mention count, not editorial preference.
Zealand Pharma has announced positive topline results from its Phase 1a trial of ZP9830, a novel Kv1.3 channel blocker. The study successfully met its primary objectives for safety and tolerability, paving the way for further development of this oral candidate for chronic inflammatory and autoimmune diseases.
Source: manilatimes.net · rttnews.com
Grünenthal has initiated clinical development for its proprietary NaV 1.8 inhibitor, a highly selective non-opioid analgesic candidate. This milestone positions the German pain specialist as a key contender in the race to develop potent, non-addictive treatments for acute and chronic pain.
Jefferies analysts have issued a high-conviction outlook on Definium Therapeutics' lead candidate, DT120, assigning a 65-75% probability that the drug will demonstrate best-in-class efficacy in its ongoing Phase III trials. This projection positions the company as a potential disruptor in its therapeutic category, significantly raising market expectations ahead of upcoming data readouts.
Source: insidermonkey.com · finance.yahoo.com
Genmab A/S reported a decline in full-year profits, marking a period of significant financial and clinical divergence across the biotechnology sector. While breakthrough results in depression therapy propelled Compass Pathways, Ocular Therapeutix suffered a sharp decline despite meeting Phase 3 trial endpoints.
According to our own tracking database, this category has accumulated 104 clinical trials stories since coverage began. This page aggregates the latest clinical trials stories within our biotech coverage area. Every story is cross-referenced across multiple primary sources, scored for sentiment and operational impact, and timestamped so fresh developments surface first. We track phase i-iii results, trial design and surface the angles a domain expert would actually read.
Story selection follows our editorial methodology — impact scoring weights regulatory, financial, and operational developments distinctly. Sentiment is classified across five tiers via supervised classification trained on labeled industry corpora. See our glossary for term definitions and our trends index for longitudinal patterns across the biotech beat.
Stories only surface on this page once the classifier scores them at a minimum 35 percent relevance to the category. According to that methodology, reviewed July 2026, this follows multi-source corroboration standards recommended by journalism research bodies such as the Reuters Institute for the Study of Journalism.
See something wrong on this page — a wrong stat, a broken source link, a miscategorized story? Report a data issue.
| Signal | What it tells you |
|---|---|
| Verified by N sources | Confidence the story isn't a single-source rumor — N≥2 means the development is independently corroborated. |
| Impact score (1-10) | Estimated regulatory, financial, or operational impact. 8+ indicates a story experienced operators should act on. |
| Sentiment | Five-tier classification (very bullish through very bearish) trained on labeled biotech-specific corpora. |
| Time stamp | Recency. Fresh stories (under 1h) render with a highlighted timestamp; stale stories (≥24h) render dimmed. |